Avalyn Pharma Inc. Common Stock
AVLN | NASDAQ
$25.63
-$0.08 (-0.31%)
At close: Oct 30, 2026, 4:00 PM ET
$23.20
-$2.43 (-9.48%)
Pre-market:
Nov 2, 2026, 6:23 AM ET
Fiscal Year Period Ending | FY 2025 Dec 31, 2025 |
|---|---|
Net Income | -85.2M |
Depreciation & Amortization | 42K |
Stock-Based Compensation | 3.27M |
Other Working Capital | 1.22M |
Other Non-Cash Items | -2.21M |
Deferred Income Tax | n/a |
Change in Working Capital | 2.61M |
Operating Cash Flow | -81.48M |
Capital Expenditures | -344K |
Cash Acquisitions | n/a |
Purchase of Investments | -109.3M |
Sales Maturities Of Investments | 119.7M |
Other Investing Acitivies | n/a |
Investing Cash Flow | 10.06M |
Debt Repayment | n/a |
Common Stock Repurchased | n/a |
Dividend Paid | n/a |
Other Financial Acitivies | -594K |
Financial Cash Flow | 99.79M |
Net Cash Flow | 28.36M |
Free Cash Flow | -81.83M |
Adj. Free Cash Flow | -85.1M |
Maintenance CapEx | -42K |
Growth CapEx | -302K |
Owner Earnings | -81.53M |
Add to Watchlist
Select watchlists to add or remove AVLN